Lagis Enterprise (6730) reported revenue of NT$41.2 million for Oct 2026, -3.3% year on year and -6.0% from the previous month. Revenue for Jan–Oct 2026 was NT$416 million (+2.4% year on year).
In Oct 2026, it ranked No. 107 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$41.2 million | -3.3% | -6.0% |
| Sep 2026 | NT$43.8 million | +7.3% | +0.6% |
| Aug 2026 | NT$43.5 million | +3.6% | -4.1% |
| Jul 2026 | NT$45.4 million | +4.2% | -2.3% |
| Jun 2026 | NT$46.5 million | +13.3% | +11.3% |
| May 2026 | NT$41.8 million | +6.5% | +6.6% |
| Apr 2026 | NT$39.2 million | -5.2% | +4.4% |
| Mar 2026 | NT$37.5 million | -9.7% | +9.5% |
| Feb 2026 | NT$34.3 million | +2.6% | -19.7% |
| Jan 2026 | NT$42.7 million | +4.9% | -2.9% |
| Dec 2025 | NT$44 million | +38.0% | +17.7% |
| Nov 2025 | NT$37.4 million | -4.1% | -12.2% |
| Oct 2025 | NT$42.6 million | +19.1% | +4.3% |
| Sep 2025 | NT$40.8 million | +9.2% | -2.9% |
| Aug 2025 | NT$42 million | +15.2% | -3.6% |
| Jul 2025 | NT$43.6 million | -1.7% | +6.1% |
| Jun 2025 | NT$41.1 million | +0.0% | +4.7% |
| May 2025 | NT$39.2 million | +1.0% | -5.1% |
| Apr 2025 | NT$41.3 million | +13.9% | -0.6% |
| Mar 2025 | NT$41.6 million | +5.5% | +24.3% |
| Feb 2025 | NT$33.4 million | -2.6% | -18.0% |
| Jan 2025 | NT$40.7 million | +2.5% | +27.7% |
| Dec 2024 | NT$31.9 million | -27.9% | -18.2% |
| Nov 2024 | NT$39 million | -4.2% | +9.1% |
| Oct 2024 | NT$35.7 million | -8.4% | -4.4% |
Jan–Oct 2026 cumulative: NT$416 million (+2.4% YoY)
Other Biotech & Medical companies
Compare with peers: Lagis Enterprise vs PEC / Lagis Enterprise vs Lotus Pharm / Lagis Enterprise vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16